Adeno-Associated Virus (AAV) Biosafety Testing & Characterization Services

Biosafety testing and characterization for new products is essential as they emerge for clinical study. Both measures will help mitigate safety concerns and confirm product quality before these therapies are administered to patients. Our BioReliance® AAV testing services give you the confidence to get your products to market quickly and safely.

Balancing Speed and Customization

Many of the testing & characterization methods in existence today have been developed with traditional modalities and products in mind and don’t always meet the needs of AAV developers. However, full method development and validation can add cost and extend timelines.

Using our platform assays allows AAV-based therapies to move through development and release testing faster. These assays are developed and validated to allow for customizing predefined components, e.g. positive control or target region, permitting a streamlined approach to validation.

Our team of experts will consult with you to develop your specific testing program from our wide array of routine and platform assays to fully characterize and analyze your AAV vector’s safety, identity, quality, purity, potency, and stability.